Hanada, Shigeo
Wajima, Takeaki
Takata, Misako
Morozumi, Miyuki
Shoji, Michi
Iwata, Satoshi
Ubukata, Kimiko
Article History
Received: 8 March 2024
Accepted: 23 May 2024
First Online: 7 June 2024
Declarations
:
: This study adhered to the tenets of the Declaration of Helsinki and Guidelines for Epidemiologic Studies issued by the Japanese Ministry of Health, Labor, and Welfare. The study protocol was approved by the Institutional Review Board of the Keio University School of Medicine Ethics Committee (approval number: 20130455); the requirement for obtaining written informed consent from patients was waived owing to the use of anonymised stored samples and data. Patient medical records in a database were obtained anonymously using a survey form completed by attending physicians.
: The following authors received financial support within the last 3 years: S. I. from Asahi Kasei Pharma Corporation, Pfizer Japan Inc., Astellas Pharma, Meiji Seika Pharma Co., Ltd., and Gilead Sciences. Inc.; K.U. from Pfizer Japan Inc., HORIBA, Ltd., and Eiken Chemical Co., Ltd. The other authors declare that they have no conflict of interest.